941-17 Left Atrial Booster Pump Function in Patients with Ischemic Cardiomyopathy and Idiopathic Dilated Cardiomyopathy  by Wang, Yuepeng et al.
lACC February 1995 ABSTRACfS 165A
In the Captopril And Thrombolysis Study, 298 patients (age: 59 ± 10) with
first anterior myocardial infarction treated with IV streptokinase were ran-
domized to either oral captopril or placebo. Left ventricular end-diastolic
and end-systolic volume index (LVEDVI and LVESVI) were assessed by 2D
echocardiography within 24 hours, at day 3 and 10, after three months and
after one year. Ninety-nine patients underwent CR by PTCA (n = 76) or CABG
(n = 23) on clinical indication at 34 days (range 1 to 293) after onset of symp-
toms. Baseline characteristics of CR patients were comparable to those of
patients not receiving active revascularization (NCR). During the follow-up
NCR patients, as contrasted to CR-patients, showed a gradual increase in
LVEDVI of 9 ml/mZ (95%CI; 5-13). Dilatation (defined as LVEDVI >64 and/or
LVESVI >29 ml/m2 ) occurred more frequently in the NCR-group (47% vs
29%, P = 0.0004).
Conclusion: Coronary revascularization in addition to thrombolytic therapy
may further reduce the risk for ventricular dilatation during the first year after
myocardial infarction
Cardiomyopathy - Dilated and Hypertrophic
normal LVEDP high LVEDP
ICM DCM (CM DCM
n 21 17 27 25
LVEDP (mmHg) 8.7 ± 3.2 ns 8Z ± 3.5 226 ± 5.1 ns 19.8 ± 7.2
LV % fraction shortening 20 ± 5 ns 18 ± 7 16 ± 5 ns 16±6
Ecorrected by age (%) 101 ± 41 ns 96 ± 34 106±53ns 94 ± 40
A corrected by age (%) 112 ± 45 ns 111 ±51 103±47' 70 ± 36
AlE corrected by age (%) 124 ± 46 ns 106 ± 58 102 ± 45' 67 ± 49
Atrial filling fraction (%) 39±13ns 35 ± 11 33 ± 13' 21 ± 12
LV + dp/dt in atrial systole 137±B9ns 128 ± 73 260 ± 92' Z17 ± 94
'p < 0.05, significant difference between ICM and DCM by ANOVA
Only in high LVEOP groups, reverse pulmonary venous flow velocity in
atrial systole measured by transesophageal echo was higher in ICM than
in DCM (20 ± 4 vs 15 ± 4 cm/s). Autopsy showed severely fibrotic LA my-
ocardium in 1 patient with OCM but not in 4 with ICM. Thus, LA booster
pump function is not enough to fill LV in atrial systole in severe DCM with
high LVEDP presumably because of involvement of LA with cardiomyopathic
process.
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OPC-18790 is a novel inotropic agent which works partially by inhibiting
phosphodiesterase without a positive chronotropic effect. The purpose of
this study was to examine the effects of OPC-1 8790 on mechanoenergetics
in patients with idiopathic dilated cardiomyopathy (DCM) in comparison with
the effects of dobutamine. Twenty patients with DCM (LVEF < 50%) received
either OPC-18790 infusion (5-10 JLglkg/min, n = 10), or dobutamine (2.5-5
JLg/kg/min, n = 10). Measurements of heart rate (HR), left ventricular end-
diastolic volume index (LVEDVll. left ventricular end-systolic elastance (Ees),
effective arterial elastance lEa), myocardial oxygen consumption (MVOz), ex-
ternal work (EWl. and pressure-volume area (PVA) were obtained by using
conductance catheter and Webster catheter before and after administration
of each drug. 0.87'0.62
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Hiroshi Oe, Masatake Fukunami, Masaharu Ohmori, Kazuaki Kumagai,
Takahisa Yamada, Yasushi Abe, Nagahiro Nishikawa. Jiyoong Kim, Motoo Date,
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To clarify how the long-term tl-blocker (I'll therapy for the patients (pts) with
dilated cardiomyopathy (DCM) improves the rate of freedom from cardiac
death (RFCDj, 57 DCM pts with tl (metoprolol; 40-60 mg/day) (G-l, follow-
up; 6-120 M) and 72 DCM pts without tl (G-2, follow-up; 6-102 M) were
followed up. The survival was confirmed by annual interview. The cause of
death and the preterminal condition of the pts were obtained from family
members, medical personnel or medical recordings. The RFCO was analyzed
with Kaplan-Meier life table method. At entry, there were no significant dif-
ferences in age, sex, blood pressure, heart rate, left ventricular end-diastolic
dimension (64.0 ± 6.0 vs 63.5 ± 6.8 mm) and ejection fraction (40.7 ± 9.1
vs 42.3 ± 8.3%) measured by echocardiography, and the severity of ven-
tricular arrhythmia by 24 hours Holter monitoring (according to the Lawn's
grade) between G-l and G-2. During the follow-up period, non-cardiac death
occurred in 2 pts in G-1 and in 3 pts in G-2. The annual RFCD were calculated
as shown below;
G-l
G-2
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Beneficial Effects of OPC-18790 on
Mechanoenergetlcs in Patients with Idiopathic
Dilated Cardiomyopathy
1941-161
mean value ± SEM. 'p < 0.05, "p < 0.01. '''p < 0.001 vs before
OPC-l 8790 decreased MV02 and improved mechanical efficiency partially
due to an adequate balance between inotropic and preload reducing effect.
OPC-18790 may be useful for treating patients with congestive heart failure.
OPC-18790 Dobutamine
before after before after
HR{min-1) 79 ± 4 85 ± 6 79 ± 5 97 ± 5***
LVEDVI(mUm2j 126 ± 11 109 ± 7*' 150 ± 7 141 ± 11
Ees(mmH9/mL) 1.73 ± 0.31 2.48 ± 0.48' 0.72 ± 009 1.42 ± 0.18'"
EalmmHg/mL) 217 ± 0.27 1.79 ± 0.22 2.16±022 2.44 ± 044
MV02lJlbeat) 4.51 ± 0.66 3.61 ± 0.62' 516±074 7.27 ± 1.30**
EW{J/beatl 0.70 ± 0.06 0.65 ± 010 0.90 ± 011 1.09 ± 0.13**
EW/PVA(%) 41.4±3.4 59.6 ± 5.1" 30.3 ± 29 47.0 ± 5.0'"
EW/MV02(%) 17.4±2.3 21.0 ± 3.0' 203 ± 3.0 17.9 ± 2.6'
Yuepeng Wang, Katsu Takenaka, Yukihiro Kuwada, Makoto Sonoda.
Tsutomu Igarashi, Fumiyoshi Watanabe, Masao Omata. University of Tokyo, Tokyo,
Japan
Ischemic process rarely involves the LA. To test the hypothesis that LA
booster pump function is impaired in idiopathic dilated cardiomyopathy
(DCM) but not in ischemic cardiomyopathy (ICM), peak Doppler mitral flow
velocities in early diastole (E) and in atrial systole (Al. and other indexes were
measured within 24 hours of cardiac catheterization in 48 patients with ICM
and 42 with OCM. Patients were divided into subgroups with normal «12
mmHg) and high (;:: 12 mmHg) LV end-diastolic pressure ILVEOP).
A Scintigraphic Prognostication is Important in
Young Patients with Idiopathic Dilated
Cardiomyopathy
'p < 0.05. # P < 0.01 vs G-2
The number of death from heart failure did not show significant difference
between G-1 (3 of 57 pts) and G-2 (4 of 72 pts). On the other hand, sudden
death has occurred more often in G-2 (1 0 of 72 pts) than in G-1 (1 of 57 pts) (p
< 0.05), resulting in that the RFCD was significantly better in G-l than in G-2.
These results indicate that the long-term tl-blocker therapy for OCM might
improve the rate of freedom from cardiac death due to prevention of sudden
death rather than of death from heart failure.
Takashi Furuno, Jun Takata, Toshikazu Yabe. Yoshihisa Matsumura,
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Identification of candidates for early cardiac transplantation and of those who
can wait is important, partiCUlarly in patients (pts) with idiopathic dilated car-
diomyopathy (DCM). To evaluate the significance of thallium-201 perfusion
defect (PD) and age in prognostication, 70 DCM pts underwent thallium scan
as well as clinical and hemodynamic examination. Results; (1) An abnormal
PD was present in 22 of 36 young pts (61 %) aged <60 years and in 25 of 34
elderly pts (74%) aged ;0:60 years (ns). (2) In the uni-variate analysis, PO was
a significant predictor of cardiac death only in young OCM pts (p = 0.0031).
Stepwise discriminant analysis also revealed that PO was again a significant
predictor in young pts (Wilks lambda 0.4958, chi-square 14.733, p = 0.0224),
although it was not more important than the history of synco'pe or stroke in
elderly DCM pts. (3) During 55 ± 41 months, 20 pts had disease-related mor-
tality. In young OCM pts, 5 years survival rate was better in pts without than
in those with PO 11.0 vs 0.56, respectively), although it was not affected by
PO in the elderly (0.67 vs 0.66).
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